Literature DB >> 11422610

Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominately in acinar zone 3.

G A MacDonald1, K R Bridle, P J Ward, N I Walker, K Houglum, D K George, J L Smith, L W Powell, D H Crawford, G A Ramm.   

Abstract

BACKGROUND AND AIMS: Hepatic steatosis has been shown to be associated with lipid peroxidation and hepatic fibrosis in a variety of liver diseases including non-alcoholic fatty liver disease. However, the lobular distribution of lipid peroxidation associated with hepatic steatosis, and the influence of hepatic iron stores on this are unknown. The aim of this study was to assess the distribution of lipid peroxidation in association with these factors, and the relationship of this to the fibrogenic cascade.
METHODS: Liver biopsies from 39 patients with varying degrees of hepatic steatosis were assessed for evidence of lipid peroxidation (malondialdehyde adducts), hepatic iron, inflammation, fibrosis, hepatic stellate cell activation (alpha-smooth muscle actin and TGF-beta expression) and collagen type I synthesis (procollagen alpha1 (I) mRNA).
RESULTS: Lipid peroxidation occurred in and adjacent to fat-laden hepatocytes and was maximal in acinar zone 3. Fibrosis was associated with steatosis (P < 0.04), lipid peroxidation (P < 0.05) and hepatic iron stores (P < 0.02). Multivariate logistic regression analysis confirmed the association between steatosis and lipid peroxidation within zone 3 hepatocytes (P < 0.05), while for hepatic iron, lipid peroxidation was seen within sinusoidal cells (P < 0.05), particularly in zone 1 (P < 0.02). Steatosis was also associated with acinar inflammation (P < 0.005). alpha-Smooth muscle actin expression was present in association with both lipid peroxidation and fibrosis. Although the effects of steatosis and iron on lipid peroxidation and fibrosis were additive, there was no evidence of a specific synergistic interaction between them.
CONCLUSIONS: These observations support a model where steatosis exerts an effect on fibrosis through lipid peroxidation, particularly in zone 3 hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11422610     DOI: 10.1046/j.1440-1746.2001.02445.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  41 in total

1.  Non-alcoholic fatty liver disease: is iron relevant?

Authors:  Julia O'Brien; Lawrie W Powell
Journal:  Hepatol Int       Date:  2011-08-12       Impact factor: 6.047

Review 2.  Mechanisms of hepatic fibrogenesis.

Authors:  Ursula E Lee; Scott L Friedman
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

3.  A retinoic acid receptor β2 agonist reduces hepatic stellate cell activation in nonalcoholic fatty liver disease.

Authors:  Steven E Trasino; Xiao-Han Tang; Jose Jessurun; Lorraine J Gudas
Journal:  J Mol Med (Berl)       Date:  2016-06-06       Impact factor: 4.599

4.  Non-alcoholic fatty liver induces insulin resistance and metabolic disorders with development of brain damage and dysfunction.

Authors:  Doaa A Ghareeb; Hani S Hafez; Hend M Hussien; Nihal F Kabapy
Journal:  Metab Brain Dis       Date:  2011-09-01       Impact factor: 3.584

5.  Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content.

Authors:  Lauren N Bell; Constance J Temm; Rashmil Saxena; Raj Vuppalanchi; Philip Schauer; Mordechai Rabinovitz; Alyssa Krasinskas; Naga Chalasani; Samer G Mattar
Journal:  Ann Surg       Date:  2010-06       Impact factor: 12.969

6.  A novel role for ceramide synthase 6 in mouse and human alcoholic steatosis.

Authors:  Bianca Williams; Jason Correnti; Amanke Oranu; Annie Lin; Victoria Scott; Maxine Annoh; James Beck; Emma Furth; Victoria Mitchell; Can E Senkal; Lina Obeid; Rotonya M Carr
Journal:  FASEB J       Date:  2017-09-01       Impact factor: 5.191

7.  Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver.

Authors:  Zvi Ackerman; Mor Oron-Herman; Talma Rosenthal; Orit Pappo; Gabriela Link; Ben-Ami Sela; Maria Grozovski
Journal:  Dig Dis Sci       Date:  2007-08-22       Impact factor: 3.199

Review 8.  Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma.

Authors:  Jinah Choi; Nicole L B Corder; Bhargav Koduru; Yiyan Wang
Journal:  Free Radic Biol Med       Date:  2014-05-06       Impact factor: 7.376

9.  Morphometric analysis of hepatic steatosis in chronic hepatitis C infection.

Authors:  Alia Zubair; Shahid Jamal; Azhar Mubarik
Journal:  Saudi J Gastroenterol       Date:  2009-01       Impact factor: 2.485

Review 10.  Chronic hepatitis C and liver fibrosis.

Authors:  Giada Sebastiani; Konstantinos Gkouvatsos; Kostas Pantopoulos
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.